角膜胶原交联治疗儿童进展性圆锥角膜:最长14年随访
这项回顾性单中心非对照干预研究评估了Dresden方案角膜胶原交联(S-CXL)治疗儿童进展性圆锥角膜的长期结局。24例患者38眼在术后平均11.6年(最长14年)随访中,矫正远视力(CDVA)和A值显著改善;13眼(34%)在A、B、C三项参数中有两项显示术后进展,但仅3眼(7.9%)A值变化有统计学意义。作者结论认为S-CXL对儿童进展性圆锥角膜是安全的,随访≥10年时前表面曲率进展率最高为7.9%。
要点
- 24例患者38眼接受S-CXL,术后平均随访11.6年(最长14年)。
- CDVA从0.703±0.33提高至0.887±0.2(P<.001),A值从2.550±1.7改善至1.627±1.68(P=.019)。
- 13眼(34%)在A、B、C中两项显示术后进展,仅3眼(7.9%)A值变化有统计学意义。
核心结论
- S-CXL对儿童进展性圆锥角膜是安全的,随访≥10年时前表面曲率进展率最高为7.9%。
研究设计与样本
- 回顾性、单中心、非对照干预性研究,纳入2007年6月至2011年1月在意大利米兰Rozzano的Humanitas临床与研究中心接受S-CXL、年龄<18岁且完成至少10年随访的患者。
主要发现
- 共38眼(24例患者)符合纳入标准,术后平均11.6年(最长14年)随访。
- CDVA从0.703±0.33(十进制小数)提高至0.887±0.2,P<.001。
- A值从2.550±1.7改善至1.627±1.68,P=.019。
- 13眼(34%)在A、B、C三项参数中有两项显示术后显著进展。
- 上述13眼中仅3眼(7.9%,3例患者)A值变化有统计学意义。
关键数值与推荐
- 复发性进展定义为:以ABCD显示评估的A值或B值超出S-CXL术后人群95%CI,或最小厚度C值下降,三项中满足两项。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the long-term outcomes of corneal collagen cross-linking according to the Dresden protocol (S-CXL) in progressive pediatric keratoconus (KC). DESIGN: Retrospective, single-center noncomparative interventional study. METHODS: Patients aged <18 years who underwent S-CXL from June 2007 to January 2011 in Humanitas Clinical and Research Center, Rozzano, Milan, Italy, and completed at least 10 years of follow-up were included. Corrected distance visual acuity (CDVA), refraction, and tomography were evaluated at baseline and ≥10 years after S-CXL. Meeting 2 of the following 3 criteria indicated reprogression: progression above 95% CI for post-CXL population of A or B values or a decrease in minimal thickness C evaluated with the ABCD display. RESULTS: Thirty-eight eyes of 24 patients fulfilled inclusion criteria. At a mean of 11.6 years postoperation (maximum 14 years), the CDVA improved significantly (from 0.703 ± 0.33 decimal fraction to 0.887 ± 0.2, P < .001). Similarly, the A value significantly improved from 2.550 ± 1.7 to 1.627 ± 1.68 (P = .019). Thirteen eyes (34%) showed significant postoperative progression in 2 of the 3 parameters A, B, and C. Of these, only 3 eyes (7.9%) of 3 patients showed a statistically significant change in the A value. CONCLUSIONS: S-CXL proved to be a safe treatment for progressive KC in pediatric patients with an anterior curvature progression rate of up to 7.9% at ≥10 years of follow-up.
引用
- Vinciguerra R, Bordignon N, Ferraro V, et al. Corneal Collagen Cross-Linking for Progressive Keratoconus in Pediatric Patients: Up to 14 Years of Follow-up. Am J Ophthalmol. 2023. PMID: 37478962. doi:10.1016/j.ajo.2023.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。